Search clinical trials for: Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

Total 55082 results

Liveome Inc.

Recruiting

A Study of LIV001 in Healthy Subjects and Those With Mild-to-Moderate Active Ulcerative Colitis (UC)

Ulcerative Colitis

Australia
Theravance Biopharma

Completed

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

United States
Hutchison Medipharma Limited

Terminated

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Recruiting

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Sublimity Therapeutics Holdco Limited
Dr. Falk Pharma GmbH

Terminated

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, United Kingdom, Serbia, Canada, Russian Federation, Poland, Israel, Romania, Ireland, Spain, Hungary, Ukraine, Belarus, Italy, Bulgaria, France, Germany
Assembly Biosciences

Terminated

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

United States, Canada
Ferring Pharmaceuticals

Completed

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Zydus Lifesciences Limited

Recruiting

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Ulcerative Colitis

India
AltruBio Inc.

Recruiting

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Ulcerative Colitis

United States, Canada
Bausch Health Americas, Inc.

Not yet recruiting

Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Ulcerative Colitis
OSE Immunotherapeutics

Recruiting

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (CoTikiS)

Ulcerative Colitis

Belgium, Latvia, Bulgaria, Belarus, Croatia, Georgia, Hungary, Poland, Russian Federation, South Africa, Ukraine
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Adiso Therapeutics

Completed

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) (SCOUT)

Ulcerative Colitis

United States, Georgia, Moldova, Republic of, Poland
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Prometheus Biosciences, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis (ARTEMIS-UC)

Ulcerative Colitis

United States, Australia, Belgium, Czechia, France, Georgia, Canada, Hungary, Israel, Italy, Poland, United Kingdom
Everstar Therapeutics Limited

Active, not recruiting

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis

China
Celgene

Active, not recruiting

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Abivax S.A.

Active, not recruiting

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Belgium, Poland, Czechia, Hungary
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Completed

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
KoBioLabs

Withdrawn

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

Australia
Abivax S.A.

Completed

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Belgium
Ionis Pharmaceuticals, Inc.

Completed

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

Ulcerative Colitis

United States
Ionis Pharmaceuticals, Inc.

Completed

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
San Giovanni Addolorata Hospital
Onlus S. Andrea

Completed

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients (LGGinUC)

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

Italy
Seres Therapeutics, Inc.

Terminated

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis (ECO-RESET)

Ulcerative Colitis

United States, Canada
Prof. Arie Levine

Completed

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Israel, Canada
Shire

Completed

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Shire

Terminated

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Hungary, Portugal, Turkey, Belgium, Bulgaria, New Zealand, Argentina, Greece, Bosnia and Herzegovina, Colombia, Estonia, Japan, Mexico, Slovakia, Ukraine, Ireland, Canada, Switzer...
Ferring Pharmaceuticals

Completed

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Bulgaria, Canada, Mexico, Poland, Serbia
Provention Bio, Inc.

Completed

A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis (PULSE)

Ulcerative Colitis

Georgia, Moldova, Republic of, Ukraine
Bausch Health Americas, Inc.

Completed

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Completed

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

Ulcerative Colitis | Inflammatory Bowel Disease

United States
Forest Laboratories

Terminated

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Proctitis, Ulcerative

United States, Poland, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Proctitis | Proctosigmoiditis

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Proctitis | Proctosigmoiditis

United States
Dayanand Medical College and Hospital
Colitis & Crohn's Foundation (India)

Unknown

Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

India
Tillotts Pharma AG

Completed

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC) (Precision-UC)

Acute Ulcerative Colitis

Switzerland
Ferring Pharmaceuticals

Completed

QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®) (QUARTZ)

Distal Ulcerative Colitis

France
PurGenesis Technologies Inc.

Completed

Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis

Left-Sided Ulcerative Colitis | Proctosigmoiditis

Germany
GlaxoSmithKline

Completed

Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

Colitis, Ulcerative

Sweden, Germany, Belgium, Canada, Norway
University of Louisville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

Mild to Moderately Active Ulcerative Colitis

United States
Tillotts Pharma AG

Completed

Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

Belarus, Turkey, India, Ukraine
University of Alberta
Canadian Institutes of Health Research (CIHR); Crohn's and Colitis Canada; Beneo...

Completed

Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

Canada
Protalix

Unknown

Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Israel
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States, Australia, New Zealand
Harbor Therapeutics

Completed

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, New Zealand, Norway, Poland, Portugal, Spain, Switzerland

Search clinical trials for: Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations